Vorasidenib (AG-881) is a potent, oral, dual inhibitor of IDH1 and -2 mutations, and has been proven to penetrate the blood-brain barrier in several preclinical studies and inhibit 2-HG production in glioma tissue by more than 97% in an orthotopic glioma mouse model [60]. Here, IDH1 is linked to central nervous system cancer.